Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
높은 성장
회사의 매출은 지난 3년간 꾸준히 성장해왔으며, 연평균 18.20%의 증가율을 기록했습니다.
공정한 가치
회사의 최신 PE은 -47.18로, 최근 3년 기준 중간 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 177.30M주이며, 전 분기 대비 20.60% 감소했습니다.
PRFDX가 보유
스타 투자자 PRFDX이(가) 이 주식 30.52K주를 보유하고 있습니다.
시장 활동 감소
회사는 투자자들의 관심이 줄어들어, 최근 20일간 회전율이 0.77입니다.